Pentadecapeptide BPC-157 Restores Blood Supply and Normalizes Oxidative Stress in Ischemic Colitis Rat Models

Ischemic colitis is a serious condition resulting from reduced blood flow to the colon, leading to inflammation, tissue damage, and potentially life-threatening complications. Ischemia-reperfusion injury, where blood flow is restored after a period of deprivation, can paradoxically worsen damage through oxidative stress. Current treatments are often supportive, and effective therapies that can rapidly restore microcirculation and mitigate tissue damage are needed. The gastric pentadecapeptide BPC-157 is being investigated for its potent cytoprotective and organoprotective effects, particularly its ability to promote angiogenesis and modulate the nitric oxide (NO) system, which plays a crucial role in regulating blood flow and vascular health. This study explores its potential as a direct, localized treatment to counteract the immediate vascular and biochemical damage in acute ischemic colitis.

The study used several rat models of ischemic colitis induced by ligating the left colic artery and vein. In IC-rats (ischemia) and IC+RL-rats (ischemia + reperfusion), a medication bath (BPC-157 10 μg/kg, L-NAME, L-arginine, or saline) was applied directly to the blood-deprived colon segment. Vessel presentation was recorded for 15 minutes with a USB microscope. A third model, IC+OB-rats, had an additional colon obstruction for 3 days before receiving a BPC-157 bath. Primary endpoints included visual assessment of blood vessels and mucosal integrity, as well as tissue levels of malondialdehyde (MDA) and nitric oxide (NO) to quantify oxidative stress.

Direct application of BPC-157 (10 μg/kg) rapidly improved the condition of the ischemic colon segment across all models. It increased vessel presentation, and crucial inside/outside arcade interconnections quickly reappeared. In BPC-157-treated rats, mucosal folds were preserved, and pale, ischemic areas were small and markedly reduced. The peptide successfully counteracted the detrimental effects of both the NO synthase inhibitor L-NAME and the NO precursor L-arginine, suggesting a complex modulatory role within the NO system. Biochemically, BPC-157 normalized tissue markers of oxidative stress.

In both ischemic (IC) and ischemia-reperfusion (IC+RL) rats, BPC-157 treatment restored both malondialdehyde (MDA) and nitric oxide (NO) levels to normal. Furthermore, in the chronic obstruction model (IC+OB), BPC-157 treatment resulted in almost completely spared mucosa with no gross defects and a normal colon diameter by day 10.

Written by TitrateLab, separately from the study summarized above.